Ramelteon

Generic Name
Ramelteon
Brand Names
Rozerem
Drug Type
Small Molecule
Chemical Formula
C16H21NO2
CAS Number
196597-26-9
Unique Ingredient Identifier
901AS54I69
Background

Ramelteon is the first in a new class of sleep agents that selectively binds to the melatonin receptors in the suprachiasmatic nucleus (SCN). It is used for insomnia, particularly delayed sleep onset. Ramelteon has not been shown to produce dependence and has shown no potential for abuse.

Indication

用于失眠症,特别适用于治疗难以入睡型失眠症。

Associated Conditions
Insomnia
Associated Therapies
-

Add-On Ramelteon in Bipolar I Disorder With Clinically Significant Sleep Disturbance

Phase 3
Terminated
Conditions
Interventions
First Posted Date
2008-01-03
Last Posted Date
2013-05-10
Lead Sponsor
Lindner Center of HOPE
Target Recruit Count
21
Registration Number
NCT00585208
Locations
🇺🇸

The Lindner Center of HOPE, Mason, Ohio, United States

Improving Sleep in Nursing Homes

Phase 4
Completed
Conditions
Interventions
First Posted Date
2007-12-19
Last Posted Date
2014-08-13
Lead Sponsor
Emory University
Target Recruit Count
79
Registration Number
NCT00576927

Ramelteon for the Treatment of Insomnia and Mood Stability in Patients With Euthymic Bipolar Disorder

Phase 4
Completed
Conditions
Interventions
First Posted Date
2007-11-02
Last Posted Date
2014-04-14
Lead Sponsor
Lehigh Valley Hospital
Target Recruit Count
90
Registration Number
NCT00552760
Locations
🇺🇸

Lehigh Valley Hospital, Department of Psychiatry, Allentown, Pennsylvania, United States

Differential Effects of Zolpidem Versus Ramelteon in Burned Children

Phase 2
Completed
Conditions
Interventions
First Posted Date
2007-10-04
Last Posted Date
2016-07-27
Lead Sponsor
Shriners Hospitals for Children
Target Recruit Count
10
Registration Number
NCT00539110
Locations
🇺🇸

Shriners Hospital for Children, Cincinnati, Ohio, United States

Functional Melatonin Replacement for Sleep Disruptions in Individuals With Tetraplegia

First Posted Date
2007-07-26
Last Posted Date
2014-05-22
Lead Sponsor
US Department of Veterans Affairs
Target Recruit Count
12
Registration Number
NCT00507546
Locations
🇺🇸

VA Palo Alto Health Care System, Palo Alto, California, United States

Ramelteon in the Treatment of Sleep and Mood in Patients With Seasonal Affective Disorder

Phase 4
Completed
Conditions
Interventions
First Posted Date
2007-07-17
Last Posted Date
2009-10-06
Lead Sponsor
Lehigh Valley Hospital
Target Recruit Count
50
Registration Number
NCT00502320
Locations
🇺🇸

Lehigh Valley Hospital, Department of Psychiatry, Allentown, Pennsylvania, United States

Efficacy of Ramelteon on Insomnia Symptoms Associated With Jet Lag in Healthy Adult Volunteers

Phase 4
Completed
Conditions
Interventions
First Posted Date
2007-06-27
Last Posted Date
2012-02-28
Lead Sponsor
Takeda
Target Recruit Count
110
Registration Number
NCT00492011

Ramelteon (ROZEREM) in the Treatment of Sleep Disturbances Associated With Parkinson's Disease

Phase 4
Terminated
Conditions
Interventions
First Posted Date
2007-04-18
Last Posted Date
2010-11-11
Lead Sponsor
Southern California Institute for Research and Education
Target Recruit Count
4
Registration Number
NCT00462254
Locations
🇺🇸

VA Long Beach Healthcare System, Long Beach, California, United States

Subjective Efficacy of Ramelteon on Sleep in Adults With Chronic Insomnia.

Phase 4
Completed
Conditions
Interventions
First Posted Date
2006-12-21
Last Posted Date
2016-06-28
Lead Sponsor
Takeda
Target Recruit Count
552
Registration Number
NCT00414102

A Double-Blind Placebo-Controlled Trial of Rozerem in Migraine Headaches

Phase 4
Terminated
Conditions
Interventions
First Posted Date
2006-10-24
Last Posted Date
2012-02-10
Lead Sponsor
Charlottesville Neuroscience
Target Recruit Count
4
Registration Number
NCT00391755
Locations
🇺🇸

Patricia Shipley, MD, Charlottesville, Virginia, United States

© Copyright 2024. All Rights Reserved by MedPath